IIT Delhi and AIIMS New Delhi have developed an innovative smart pill that can collect microbiome samples directly from the small intestine. This ingestible device enables site specific gut analysis, improves diagnosis of digestive diseases, and marks a major breakthrough in Indian medical technology.
Table of contents [Show]
Medical science is witnessing a major technological breakthrough in the field of digestive health with the development of a swallowable microdevice by researchers at IIT Delhi and AIIMS New Delhi. This pill like device, no larger than a grain of rice, can travel through the stomach, reach the intestine, collect microbes and biochemical samples, and then safely exit the body. What once seemed like science fiction is now a validated scientific reality. This innovation opens an entirely new way of studying the human gut microbiome directly from inside the intestine.
The research team has published their study titled “A Small Pill like Ingestible Microdevice for Site specific Microbiome Sampling in the Upper GI Tract” in the reputed international journal Small. The project has been funded by the Indian Council of Medical Research, highlighting its national importance and clinical potential.
The human body is not made of human cells alone. Nearly half of the cells in the human body are microbial. These microorganisms live mainly in the gut and play a critical role in digestion, immunity, metabolism, and even mental health. The gut microbiome has been linked to diseases such as inflammatory bowel disease, diabetes, infections, obesity, and neurological disorders.
Despite its importance, studying the gut microbiome has always been a challenge. Current methods are either invasive, such as endoscopy and ileostomy, or indirect, such as stool sample analysis. Stool samples do not accurately represent what is happening in the upper part of the intestine, especially the small intestine, which is one of the most important yet least explored regions of the digestive system.
Traditional methods of studying gut bacteria suffer from serious limitations. Endoscopy is invasive, uncomfortable, and cannot be repeated frequently. Stool based testing only reflects the microbial population of the colon and not the small intestine. This means that a large and crucial part of the digestive tract remains poorly understood in routine clinical practice.
Because of these limitations, doctors and researchers have been unable to get a clear, site specific picture of microbial activity inside the small intestine. This gap in knowledge has slowed progress in understanding many chronic and metabolic diseases.
The new ingestible microdevice developed at IIT Delhi is designed to solve this exact problem. According to Prof. Sarvesh Kumar Srivastava, Principal Investigator at the Medical Microdevices and Medicine Laboratory at IIT Delhi, the human body contains a hidden universe of living microbes. He compares this innovation to sending rovers into outer space, except this time, the exploration is happening inside the human body.
Once swallowed, the device remains closed in the acidic environment of the stomach. When it reaches the intestine, the outer enteric coating dissolves due to the higher pH. This allows intestinal fluid and microbes to enter the device. A specialized hydrogel mechanism then seals the inlet, preventing contamination while the device continues its journey through the gut.
The pill sized microdevice measures approximately 7 millimeters by 2.7 millimeters and is encased in an enteric coated gelatin shell. Despite its extremely small size, it is capable of collecting enough biological material for advanced genetic and biochemical analysis.
In animal experiments, four out of five devices successfully completed intestinal transit and returned sufficient genetic material for detailed microbial sequencing. This proves that the device is not only safe but also reliable for practical biological sampling.
One of the most important advantages of this technology is that it allows species level identification of gut microbes using nanopore sequencing. This is far more precise than conventional stool tests. The device can also detect important biochemical markers such as intestinal alkaline phosphatase, which plays a key role in gut health and inflammation.
This means the smart pill does not just collect bacteria, but also provides insight into the chemical environment inside the intestine, giving a much more complete picture of gut health.
The research team has already validated the technology in animal models and has filed a patent for this innovation. The microdevice used in experiments is no larger than a grain of rice, yet it performs complex sampling and sealing functions autonomously without any external control.
The researchers are now working towards advancing this platform for clinical use in humans after obtaining necessary regulatory approvals.
Dr. Samagra Agarwal from the Department of Gastroenterology and Human Nutrition at AIIMS New Delhi, who is the co senior author of the study, explains that the small intestine plays a crucial role in both health and disease. Many important biochemical and immune processes take place in this part of the gut.
Directly studying microbes and chemicals in the small intestine could help in early disease detection, monitoring of chronic illnesses, and development of more targeted and personalized treatments.
Although current research has been conducted only in animal models, the results provide a strong proof of concept. Once approved for human use, this technology could completely transform how digestive diseases are diagnosed and monitored.
In the future, doctors may be able to use such smart pills to track disease progression, assess response to treatment, and design personalized therapies based on an individual’s internal gut environment rather than indirect test results.
This project, funded by the Indian Council of Medical Research and developed jointly by IIT Delhi and AIIMS New Delhi, represents a major Indian contribution to global medical technology. It shows how engineering and medicine can come together to solve long standing clinical problems.
The smart pill microdevice is not just a new diagnostic tool. It is a new way of looking inside the human body, opening possibilities that were previously unreachable using conventional medical methods.
The development of this ingestible microbiome sampling device marks a turning point in digestive health research. By enabling direct, site specific, and minimally invasive sampling from the small intestine, this technology bridges a critical gap in modern medicine. As this platform moves closer to clinical use, it has the potential to reshape the diagnosis and management of gut related diseases and push personalized medicine to a new level.
This article is based on the research paper titled “A Small Pill-like Ingestible Microdevice for Site-specific Microbiome Sampling in the Upper GI Tract” published in the journal Small by researchers from IIT Delhi and AIIMS New Delhi.
The project is funded by the Indian Council of Medical Research (ICMR)
ProtoRadNet, an explainable AI model developed at IISER Bhopal, can interpret MRI, CT and X ray scans like a radiologist. Built over 1.5 years and tested on public datasets with 92% accuracy and 190+ clinical reports, the system highlights suspicious regions and explains findings. This innovation could help address India’s radiologist shortage and improve diagnostic speed.
A first-of-its-kind genomic study from India has revealed that the Mpox case detected in Kerala was caused by the Clade Ib variant imported through international travel from Dubai. Genetic sequencing traced the virus’s journey into India, uncovered dangerous mutations, and warned that this evolving strain may spread faster and wider through sustained human transmission.
A major Indian Journal of Medical Research 2025 study reveals rising lung cancer incidence in India, sharp regional and gender disparities, increasing adenocarcinoma dominance, and worrying projections up to 2030.
